Identifiable biomarker and treatment development using HIV-1 long term non-progressor sera

[1]  W. Borkowsky,et al.  Growth patterns in pubertal HIV-infected adolescents and their correlation with cytokines, IGF-1, IGFBP-1, and IGFBP-3 , 2013, Journal of pediatric endocrinology & metabolism : JPEM.

[2]  J. Kappes,et al.  Antibody-Dependent Cellular Cytotoxicity against Primary HIV-Infected CD4+ T Cells Is Directly Associated with the Magnitude of Surface IgG Binding , 2012, Journal of Virology.

[3]  J. Guerra-Laso,et al.  Non-chemotactic influence of CXCL7 on human phagocytes. Modulation of antimicrobial activity against L. pneumophila. , 2012, Immunobiology.

[4]  R. Redfield,et al.  Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of β chemokines and RNases , 2012, Proceedings of the National Academy of Sciences.

[5]  R. Ahmed,et al.  T‐cell reconstitution without T‐cell immunopathology in two models of T‐cell‐mediated tissue destruction , 2009, Immunology.

[6]  F. Hsieh,et al.  Efficacy of Hepatitis B Immune Globulin for Prevention of Perinatal Transmission of the Hepatitis B Virus Carrier State: Final Report of a Randomized Double‐Blind, Placebo‐Controlled Trial , 2007, Hepatology.

[7]  H. Katinger,et al.  Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity , 2006, AIDS.

[8]  K. Ugen,et al.  Characterization of a novel human anti-HIV-1 gp41 IgM monoclonal antibody designated clone 37. , 2004, DNA and cell biology.

[9]  H. Katinger,et al.  Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques , 2003, AIDS.

[10]  H. Katinger,et al.  Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation , 2002, AIDS.

[11]  H. Katinger,et al.  The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120 , 2002, Journal of Virology.

[12]  H. Katinger,et al.  A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1 , 2002, AIDS.

[13]  C. E. Parker,et al.  Fine Definition of the Epitope on the gp41 Glycoprotein of Human Immunodeficiency Virus Type 1 for the Neutralizing Monoclonal Antibody 2F5 , 2001, Journal of Virology.

[14]  M Stürzl,et al.  Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. , 2001, Molecular biology of the cell.

[15]  S. Zolla-Pazner,et al.  Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6 , 2001, Journal of Virology.

[16]  Robert A. Rasmussen,et al.  Postnatal Passive Immunization of Neonatal Macaques with a Triple Combination of Human Monoclonal Antibodies against Oral Simian-Human Immunodeficiency Virus Challenge , 2001, Journal of Virology.

[17]  S. Zolla-Pazner,et al.  Immunoreactivity of Intact Virions of Human Immunodeficiency Virus Type 1 (HIV-1) Reveals the Existence of Fewer HIV-1 Immunotypes than Genotypes , 2000, Journal of Virology.

[18]  D. Weiner,et al.  Characterization of a novel human immunodeficiency virus type 1 neutralizable epitope within the immunodominant region of gp41. , 2000, Virology.

[19]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[20]  Tahir A. Rizvi,et al.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.

[21]  J. Mascola,et al.  Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.

[22]  H. Katinger,et al.  Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. , 1999, Immunity.

[23]  N. Haigwood,et al.  Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys , 1999, Nature Medicine.

[24]  Susan Zolla-Pazner,et al.  Synergistic Neutralization of Simian-Human Immunodeficiency Virus SHIV-vpu+ by Triple and Quadruple Combinations of Human Monoclonal Antibodies and High-Titer Anti-Human Immunodeficiency Virus Type 1 Immunoglobulins , 1998, Journal of Virology.

[25]  S. Zolla-Pazner,et al.  Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. , 1997, International immunology.

[26]  E A Emini,et al.  Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. , 1997, AIDS research and human retroviruses.

[27]  J. Bradac,et al.  Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. , 1997, The Journal of infectious diseases.

[28]  J. Hoxie,et al.  A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[29]  A. Trkola,et al.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[30]  S. Zolla-Pazner,et al.  A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates. , 1995, AIDS research and human retroviruses.

[31]  J. Safrit,et al.  Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody. , 1995, The Journal of infectious diseases.

[32]  Q. Sattentau,et al.  Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. , 1995, Virology.

[33]  C. Barbas,et al.  Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120 , 1995, Journal of virology.

[34]  A. Trkola,et al.  A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. , 1994, AIDS research and human retroviruses.

[35]  D R Burton,et al.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.

[36]  D R Burton,et al.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.

[37]  D. Fulton,et al.  Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children , 1994 .

[38]  E. Emini,et al.  Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  C. Hall,et al.  Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children , 1993 .

[40]  G Himmler,et al.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.

[41]  W. Schleif,et al.  Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody , 1992, Nature.

[42]  S. Zolla-Pazner,et al.  Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies , 1991, Journal of virology.

[43]  S. Zolla-Pazner,et al.  Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. , 1990, Journal of immunology.

[44]  S. Zolla-Pazner,et al.  Generation of human monoclonal antibodies to human immunodeficiency virus. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[45]  T. Lehner,et al.  Use of monoclonal antibodies in local passive immunization to prevent colonization of human teeth by Streptococcus mutans , 1987, Infection and immunity.

[46]  S. Sallan,et al.  Use of monoclonal antibodies as diagnostic and therapeutic reagents in acute lymphoblastic leukemia. , 1981, Cancer research.

[47]  F. Hsieh,et al.  HEPATITIS B IMMUNE GLOBULIN (HBIG) EFFICACY IN THE INTERRUPTION OF PERINATAL TRANSMISSION OF HEPATITIS B VIRUS CARRIER STATE Initial Report of a Randomised Double-Blind Placebo-Controlled Trial , 1981, The Lancet.